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Chronic treatment with tetrahydrobiopterin reverses endothelial
dysfunction and oxidative stress in hypercholesterolaemia
Abstract
BACKGROUND: Reduced availability of tetrahydrobiopterin (BH(4)), an essential cofactor of nitric
oxide (NO) synthase (NOS), decreases NO production and increases reactive oxygen species. Both
mechanisms contribute to atherosclerotic vascular disease. Although acute supplementation of BH(4)
improves endothelial dysfunction, the effect of chronic BH(4) in humans is unknown. OBJECTIVE: To
investigate the effect of chronic BH(4) supplementation on endothelial function and oxidative stress in
hypercholesterolaemia. DESIGN: Randomised double-blind, placebo-controlled trial. SETTING:
University Hospital. PATIENTS: 22 hypercholesterolaemic patients (low-density lipoprotein (LDL)
>4.5 mmol/l) were randomised to 4 weeks of oral BH(4) (400 mg twice daily) or placebo. Age-matched
healthy volunteers served as controls. MAIN OUTCOME MEASURES: Endothelium-dependent and
-independent vasodilatation was assessed by venous occlusion plethysmography. To elucidate the
mechanisms of BH(4) effect, NO release and superoxide anion (O(2)(-)) production were measured in
human aortic endothelial cells exposed to native LDL (2.6 mmol cholesterol/l). RESULTS: BH(4)
plasma levels were significantly increased by oral supplementation. NO-mediated vasodilatation to
acetylcholine was reduced in patients compared with controls and restored by BH(4). No effect of
BH(4) on endothelium-independent vasodilatation was seen. Furthermore, 8-F(2 )isoprostane plasma
levels, a marker of vascular oxidative stress, were reduced by BH(4). In LDL-treated endothelial cells,
BH(4) levels and NO release were reduced and O(2)(-) production increased compared with control
cells. Exogenous BH(4) normalised NO and O(2)(-) production. CONCLUSIONS: In
hypercholesterolaemia, endothelial dysfunction and oxidative stress can be reversed by chronic oral
treatment with BH(4). Thus, BH(4) availability is essential for maintaining NO synthesis and low
O(2)(-) production by endothelial NOS in vivo, and may provide a rational therapeutic approach to
prevent cardiovascular disease.
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ABSTRACT 
 
 
Objectives: Reduced availability of tetrahydrobiopterin (BH4), an essential cofactor of 
NO synthase (NOS), decreases NO production and increases ROS. Both mechanisms 
contribute to atherosclerotic vascular disease. Although acute supplementation of BH4 
improves endothelial dysfunction, the effect of chronic BH4 in humans is unknown. We 
investigated the effect of chronic BH4 supplementation on endothelial function and 
oxidative stress in hypercholesterolemia.  
 
Design: Randomized double-blind placebo controlled. 
 
Setting: University Hospital 
 
Patients: 22 hypercholesterolemic patients (LDL>4.5mmol/L) were randomized to 4-
weeks of oral BH4 (400 mg bid) or placebo. Age-matched healthy volunteers served as 
controls. 
 
Main outcome measures: Endothelium-dependent and –independent vasodilation 
was assessed by venous occlusion plethysmography. To elucidate the mechanisms of 
BH4 effect, NO release and superoxide anion (O2-) production were measured in human 
aortic endothelial cells exposed to native LDL (100 mg cholesterol/dL).  
 
Results: BH4 plasma levels were significantly increased by oral supplementation. NO-
mediated vasodilation to acetylcholine was reduced in patients compared with controls 
and restored by BH4. No effect of BH4 on endothelium-independent vasodilation was 
observed. Furthermore, 8-F2 isoprostane plasma levels, a marker of vascular oxidative 
stress, were reduced by BH4. In LDL-treated endothelial cells, BH4 levels and NO 
release were reduced and O2- production increased compared to control cells. 
Exogenous BH4 normalized NO and O2- production.  
 
Conclusions: In hypercholesterolemia, endothelial dysfunction and oxidative stress 
can be reversed by chronic oral treatment with BH4. Thus, BH4 availability is essential 
for maintaining NO synthesis and low O2- production by eNOS in vivo, and may provide 
a rational therapeutic approach to prevent cardiovascular disease. 
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In the last decade, the endothelial L-arginine-nitric oxide (NO) pathway has reached the 
clinical arena and NO is now regarded as a marker of cardiovascular health. Indeed, 
loss of NO bioavailability, due to reduced synthesis by nitric oxide synthase (NOS) or 
scavenging by oxidative species, is a cardinal feature of endothelial dysfunction that 
precedes the development of overt atherosclerosis and is an independent predictor of 
adverse cardiovascular events [1]. BH4 is an essential cofactor for all three NOS 
isoforms and for the aromatic amino acid hydroxylases, which are key enzymes in the 
biosynthesis of several neurotrasmitters, including catecholamines and serotonin [2]. In 
children, inborn errors in the metabolism of BH4 lead to cofactor deficiency, 
hyperphenylalaninemia, and neurological impairment [3]. Supplementation with this 
cofactor is an established treatment for BH4-responsive hyperphenylalaninemia, which 
includes BH4-responsive phenylalanine hydroxylase deficiency and defects in the 
synthesis of BH4 [4] However, an important role for BH4 in the cardiovascular system, 
as a regulator of NOS activity, has emerged only recently [2][5]. 
 
All major risk factors for atherosclerotic vascular disease, including 
hypercholesterolemia, have been associated with loss of NO bioavailability and 
endothelial dysfunction.[1] The underlying defect involves both reduced NO synthesis 
as well as increased superoxide anion (O2-) production. Several oxidase systems (e.g. 
NADPH oxidase) are potential sources of O2- and, hence, contribute to oxidative stress 
[6]. However, eNOS itself can generate O2- under certain pathophysiological conditions 
[7] The importance of BH4 in the catalytic process of L-arginine oxidation and NO 
synthesis is well established [2][7]. When intracellular BH4 levels are low, electron 
transfer within the active site of NOS becomes uncoupled from L-arginine oxidation; 
instead molecular oxygen is reduced to form O2- [7]. Such eNOS-dependent generation 
of O2- has been implicated in a variety of experimental and clinical vascular disease 
states, including hypercholesterolemia [8], diabetes mellitus [9], cigarette smoking [10], 
hypertension [11][12][13], aging [14] and overt atherosclerosis [15]. Moreover, excess 
O2- reacts with NO leading to the formation of the powerful oxidant peroxynitrite 
(ONOO-), which may be toxic to endothelial cells through the direct nitrosylation of 
lipids or proteins, and DNA damage [16]  
 
Several recent studies have suggested that acute, mostly parenteral supplementation 
of BH4 may restore NO-mediated endothelial function [8][10][15][17][18][19][20]. 
However, no clinical studies on the long-term cardiovascular effects of chronic BH4 
therapy have yet been performed. These data are critical for the development of BH4 
supplementation as a novel approach to prevent initiation and progression of 
cardiovascular disease in clinical practice. Accordingly, we prospectively studied 22 
patients with hypercholesterolemia and sought to determine whether chronic oral 
pharmacologic doses of BH4 could improve endothelial function and oxidative stress.  
In addition, to understand the cellular mechanisms of BH4 supplementation in 
hypercholesterolaemia, we performed a series of in vitro experiments using human 
endothelial cells. 
 
 group.bmj.com on March 21, 2011 - Published by heart.bmj.comDownloaded from 
 4
METHODS 
 
Patients  
A total of 22 patients, mean age 57.1 years, with hypercholesterolemia defined by LDL-
cholesterol > 4.5mmol/l were studied (Table 1). None had a history of cardiovascular 
disease nor clinical evidence of atherosclerosis on physical examination. Exclusion 
criteria were age < 20 years and > 75 years, premenopausal status, hypertension 
(blood pressure >140/90mmHg), diabetes, smoking, lipid-lowering therapy within 2 
weeks before study entry. A matched control group consisting of 9 volunteers with 
normal lipid levels was also included for comparison of baseline endothelial function 
(Table 1).  
 
Study Protocol  
Hypercholesterolemic patients were randomized to receive either 400mg BH4 (Schircks 
Laboratories, Jona, Switzerland) bid, or a matching placebo (saccharose 550mg bid) in 
a double-blind fashion for a duration of 4 weeks. In order to ensure the biochemical 
stability of BH4 patients were instructed to store the medication at -20°C. Assessment 
of forearm blood flow by venous occlusion plethysmography and measurement of F2 
isoprostanes and BH4 plasma levels was performed at baseline and after 4 weeks of 
treatment. Further standard laboratory measurements including lipid levels were 
analyzed at the same time-points. In the control group, forearm blood flow as well as 
laboratory analysis were performed as described above but only once. The study 
complies with the Declaration of Helsinki and was approved by the local ethics 
committee of the University Hospital Zürich. All patients gave their written informed 
consent prior to study entry. 
 
Assessment of Forearm Blood Flow  
Forearm blood flow (FBF) was assessed using venous occlusion plethysmography 
(EC4; Hokanson Inc., USA) with calibrated mercury-in-silastic strain gauges as 
described elsewhere[21]. In brief, all measurements were performed at the same time 
in the morning and patients were instructed to refrain from drinking alcohol or caffeine 
as well as eating for 12 hours before the examination. For assessment of endothelium-
dependent vasodilation, acetylcholine (Ach; Miochol E, Ciba Vision, Switzerland) was 
infused into the brachial artery of the non-dominant arm at increasing concentrations of 
0.15, 0.45, 1.5, 4.5, and 15µg/100ml forearm volume per minute for 5 minutes each. 
Sodium nitroprusside (SNP; Nipruss, Schwarz Pharma, Germany) was infused at 
concentrations of 1, 3, and 10µg/100 ml per minute for 3 minutes each to assess 
endothelium-independent vasodilation. Resulting forearm blood flow (FBF, mL ⋅ min-1⋅ 
100mL-1 forearm volume) was measured simultaneously in both arms with the non-
infused arm serving as control.  Recordings took place at baseline and during the last 
minute of each drug infusion.  A minimum of 5 consecutive single readings were 
obtained for each concentration and analysis was performed by a single reviewer 
blinded for patients and study visits as well as treatment regimen. Results during intra-
arterial infusions (infused/control arm) were compared to baseline readings 
(infused/control arm) and calculated as percentage change in flow ratio from baseline.  
Biochemical Analysis 
All blood samples were drawn into EDTA (1mg/ml), separated within 1 hour after 
sampling and stored at –80°C until determination was performed.  
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Biopterin contents were determined by high-performance liquid chromatography 
(HPLC). Total biopterin represents the sum of BH4, 7,8-dihydrobiopterin, and fully 
oxidized biopterin. Under acidic conditions BH4 and 7,8-dihydrobiopterin are oxidized to 
biopterin. 100 ml of plasma were acidified by addition of 20 ml of 1 M hydrochloric acid 
and 50 ml of iodine solution (1% (w/v) iodine in 2% (w/v) potassium iodide) were 
added. Samples were mixed and incubated for 1 h in the dark at room temperature. 
The reaction was stopped by adding 10 ml of 5% (w/v) ascorbic acid and 20 ml water. 
HPLC of pterins was performed as described previously [22].  
 
Plasma F2 isoprostane (8-F2 IsoP) was measured using an enzyme immunoassay kit 
(Cayman Chemical Company, Ann Arbor MI, USA).  
 
Cell Culture  
Human aortic endothelial cells (HAEC) were obtained from Clonetics (San Diego, CA, 
USA) and grown in gelatin-coated flasks in optimized endothelial growth medium 
(Clonetics) supplemented with 10% fetal calf serum (Hyclone). Cells were detached by 
exposure to trypsin/EDTA for about 120 sec in Hepes buffer saline, reseeded in 
collagen–coated 6 cm cell culture dishes. Cells were grown to confluency in humidified 
air (5% CO2 at 37°C). Cells between passages 2 and 6 were used for experiments.  
 
LDL Isolation 
The lipoproteins were prepared as follows: plasma from a pool of at least 20,000 
donors was used as starting material. The density of the plasma was adjusted with 
NaBr to 1.063 g/ml, and the LDL/VLDL fraction was separated by preparative 
ultracentrifugation in a Centrikon T-2080 ultracentrifuge (Kontron Instruments, Zürich, 
Switzerland) using a TFT 70.38 rotor (4°C, 16 h, 55’000 rpm). The top layer containing 
LDL and VLDL was collected, the density adjusted to 1.019 g/ml, and LDL was 
separated from VLDL by ultracentrifugation under the same conditions as above. The 
bottom fraction containing LDL was dialysed against 0.9 % NaCl, and stored under 
inert gas at 4°C. All preparative procedures were performed under sterile conditions. 
Cholesterol content was determined according to the method of Kattermann et al, with 
the use of CHOD-PAP method (Boehringer Mannheim).  
 
NO Measurements 
Direct in situ measurements of NO were carried out as described [11] Immediately 
before NO measurements, the active tip of the L-shaped porphyrinic NO microsensor 
was placed directly on the surface of the endothelial cell monolayer. For maximal 
stimulation of eNOS calcium ionophore A23187 was injected into the cell culture dish to 
yield a final concentration of 1 µmol/L. 
 
Measurement of O2- Production 
O2- production was measured as the SOD-inhibitable reduction of cytochrome c. Briefly, 
HAECs were preincubated in DMEM without phenol red for 30 minutes at 37°C, and 
then cytochrome c (final concentration, 1 mg/mL) with or without SOD (final 
concentration, 500 U/mL) was added in a CO2 incubator. After 60 min, the medium was 
removed from the cells, and the absorbance was read at 550 nm against a distilled 
water blank. Reduction of cytochrome c in the presence of SOD was subtracted from 
the values without SOD. The portion of O2--specific reduction of cytochrome c- was 
between 20% and 35% according to the experiments. The optical density difference 
between comparable wells with or without SOD was converted to equivalent O2- 
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production by use of the molar extinction coefficient for cytochrome c [21.0x103 (mol/L)-
1 
· cm-1].  
 
Statistical Analysis 
Clinical data and results are expressed as mean ± SD. For cell culture experiments n 
indicates number of experiments and data are expressed as mean±SEM . The ratio of 
blood flow in the infused arm compared to the control arm was calculated for each 
concentration of Ach and SNP, respectively. The response to Ach and SNP was then 
calculated as area under the dose-response curve (AUC) and expressed in arbitrary 
units. Two-sided paired and unpaired Students t-test was used for intra-and inter-group 
comparison. Statistical significance was accepted at p<0.05. 
 
RESULTS 
 
Patient Characteristics 
21 patients and 9 control subjects completed the study. One patient in the placebo 
group was excluded due to unsuccessful arterial puncture at the second visit. The 
characteristics of the study population are summarized in Table 1.   
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Table 1:  Baseline Characteristics 
     
       
Hypercholesterolemics 
  
Control 
Subjects Total BH4 Placebo 
P 
Hypercho
l. 
vs.Contro
ls 
P 
BH4 vs. 
Placebo 
Age (years) 54.4±9.5 57.4±10.1 60.8±9.2 53.9±9.6 0.49 0.14 
Sex (m/f) 7/2 17/4 7/4 10/0   
Weight (kg) 76.7±11 77.7±12.4 74.9±13.4 80.9±10.3 0.83 0.32 
BMI (kg/m2) 24.0±2.2 25.7±2.6 25.7±2.2 25.8±3.1 0.11 0.9 
BP syst (mmHg) 121.9±12.6 129.5±8.1 
126.3±8.
4 132.6±6.3 0.07 0.09 
BP dia (mmHg) 58.4±7.5 75.5±3.9 64.6±6.3 75.5±3.9 0.001 <0.001 
HR (bpm) 66.8±11.2 66.6±9.7 61.6±8.9 71.5±7.6 0.96 <0.05 
Hemoglobin (g/dl) 13.9±1.2 14.3±1.0 13.8±0.8 14.8±1.0 0.53 <0.05 
Creatinine (µmol/l) 82.2±11.9 92.3±13.7 86.5±11.8 98.0±13 0.08 0.07 
Glucose (mmol/l) 5.4±0.7 4.8±0.3 4.8±0.2 4.8±0.3 <0.05 0.71 
Total Cholesterol 
(mmol/l) 4.9±0.8 7.7±1.0 7.4±0.8 7.9±1.2 <0.0001 0.15 
HDL (mmol/l) 1.6±0.4 1.5±0.3 1.7±0.3 1.4±0.3 0.68 0.06 
LDL (mmol/l) 2.8±0.8 5.3±1.1 5.1±0.7 5.5±0.3 <0.0001 0.61 
Triglycerides (mmol/l) 1.2±0.6 1.9±0.9 1.6±0.7 2.3±0.8 <0.05 0.05 
       
AUC Acetylcholine (aU) 2029±682 1519±550 1473±512 1586±600 <0.05 0.7 
AUC SNP (aU) 1527±612 1428±600 1368±421 1540±699 0.47 0.57 
 
BMI: body mass index, BP: blood pressure, HR: heart rate, HDL: high-density 
lipoprotein, LDL: low-density lipoprotein, ALT: alanine aminotransferase, AUC: area 
under the curve, aU: arbitrary units, SNP: sodium nitroprusside. Data are mean±SD. 
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Adverse Events 
The study medication were well tolerated and no adverse events occurred in either 
treatment group.  
 
Laboratory Parameters  
BH4 plasma levels at baseline were not different between the two treatment groups 
(4.9±2.3 nmol/L for the BH4 treatment group vs. 6.6±2.7 nmol/L for placebo, p=NS). We 
observed a significant increase in through plasma BH4 levels after oral supplementation 
(42±26 vs 4.9±2.3nmol/L at baseline, p<0.05), whereas no changes occurred in the 
placebo group (Figure 1A). Chronic BH4 treatment slightly but significantly reduced total 
cholesterol (7.4±0.8 vs 7.0±0.9 mmol/L, p<0.05) and HDL cholesterol (1.7±0.3 vs 
1.5±0.2 mmol/L, p<0.05), but there was no effect on LDL cholesterol (5.1±0.7 vs 
4.9±0.8, mmol/L, p=NS). Creatinine and glucose remained unchanged throughout the 
study.  
 
Baseline 8-F2isoprostane plasma levels were similar between the two treatment arms 
(1.7±0.8 and 1.8±0.9 ng/mL, p=NS). Supplementation with BH4 significantly decreased 
8-F2 isoprostane plasma levels compared to placebo (∆, change from baseline: -0.4±0.6 
ng/mL vs +0.13±0.4 ng/mL, p<0.05, Figure 1B). 
 
Effects on Endothelial Function and Vascular Measurements 
The vasodilatory response to Ach was significantly impaired in hypercholesterolemic 
subjects compared to controls (AUC: 1473±512 vs. 2029±682; p<0.05, Table 1 and 
Figure 2). In hypercholesterolemics, the response to Ach at baseline did not differ 
between the two treatment arms. Responses to SNP, as well as blood flows at rest in 
the non-infused arm were similar in all studied groups. BH4 restored endothelium-
dependent, NO-mediated vasodilatation (AUC: 1473±512 vs 2116±758, at baseline and 
after 4-week treatment, respectively, P=0.001, Figure 2), but had no effect on 
endothelium-independent vasodilatation to SNP (AUC: 1368±421 vs 1371±441, before 
and after BH4 treatment, respectively). In contrast, in the placebo group the response to 
Ach (AUC: 1586±600 vs. 1691±638 at baseline and after 4-week treatment, p=NS) as 
well as SNP remained unchanged. Heart rate and blood pressure did not significantly 
differ after BH4  and placebo treatment (data not shown).  
 
Effects of LDL on Release of NO and O2- in Human Aortic Endothelial Cells 
To determine the mechanistic role of hypercholesterolemia on the regulation of eNOS 
function by BH4, human aortic endothelial cells were incubated with native LDL at 100 
mg cholesterol/dL for 6 hours. Intracellular BH4 levels were markedly lower in 
endothelial cells (EC) exposed to LDL compared with control cells (9.9±3.1 vs 0.9±0.6 
pmol/mg protein, p<0.05, Figure 3A). NO release and O2- production were measured in 
control cells and LDL-treated EC under basal conditions and after inhibition of eNOS by 
L-NAME (3x10-4mol/L) or in the presence of exogenous BH4 (10-4mol/L). Basal NO 
release from LDL-treated cells was reduced compared with that from control cells 
(288±29 vs 123±12 nmol/L, p<0.05, Figure 3B). In contrast, in LDL-treated cells the 
basal production of O2- was higher than in controls (6.8±0.4 vs 2.9±0.5 nmol/60 min/105 
cells, p<0.05, Figure 3C). Importantly, in LDL-treated cells, O2- production was 
significantly decreased after incubation with L-NAME (2.6±0.4 nmol/60 min/105 cells, 
Figure 3C), suggesting that increased O2- production in these cells was generated at 
least in part by uncoupled NOS. In contrast, pre-incubation of control cells with L-
NAME resulted in an increase in O2- generation (5.8± 0.7 nmol/60min/105cells, Figure 
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3C), suggesting that in control cells NOS remained enzymatically coupled and a net 
producer of NO.   
 
In the presence of exogenous BH4, NO release was increased in LDL-treated cells 
(266±4.5 nmol/L, Figure 3B), and O2- production decreased to basal levels (1.5±0.4 
nmol/60min/105cells, Figure 3C). BH4 supplementation did not affect NO or O2- 
production in control EC (Figure 3B and C). 
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DISCUSSION 
 
Hypercholesterolemia is a major risk factor for the development of atherosclerosis. 
Early on, it impairs endothelial function, being an initial step in the pathogenesis of 
vascular disease. A key feature of endothelial dysfunction is reduced NO bioavailability 
caused both by scavenging of NO by oxidative species, and also decreased NO 
synthesis. Both mechanisms may be explained by eNOS enzymatic uncoupling, 
mediated by a relative deficiency of BH4. To test this concept we investigated whether 
chronic oral therapy with BH4 was able to restore NO bioavailability and endothelial 
function in subjects with hypercholesterolemia. The key findings are: first, chronic BH4 
therapy leads to a marked 8-fold increase in plasma BH4 levels. Second, NO 
bioavailability, as determined by endothelium-dependent vasodilatation, was impaired 
in hypercholesterolemic subjects compared with controls but restored to normal by BH4 
treatment. Importantly, this effect of BH4 treatment on NO bioavailability was 
independent of any change in LDL-cholesterol, and was associated with a reduction in 
systemic oxidative stress as assessed by 8-F2 isoprostane plasma levels. Third, 
exposure of human aortic endothelial cells to LDL led to reduced cellular BH4 levels, 
reduced NO production, and increased superoxide production, at least in part from 
uncoupled NOS activity. Fourth, in human endothelial cells exposed to LDL, BH4 
supplementation was able to directly enhance NO production and reduce superoxide 
production. Taken together, these results indicate that chronic oral therapy with BH4 is 
well tolerated and effective in normalizing NO-mediated endothelial dysfunction in 
subjects with hypercholesterolemia.   
 
Acute administration of BH4 has been shown to improve endothelial function in the 
brachial artery of smokers [10], patients with type II diabetes [17] or 
hypercholesterolemia [8] and in the coronary arteries of patients with 
hypercholesterolemia [18] or angiographically overt coronary atherosclerosis [15]. 
However, interpretation of these clinical studies is limited by the high systemic doses of 
sepiapterin or BH4 used (often >100 fold in excess of physiological concentrations), 
which may increase NO bioactivity via non-specific antioxidant effects. When 
sepiapterin has been used to augment BH4 concentrations in pre-clinical models of 
vascular disease, unexpected uncoupling of eNOS has been observed, possibly as a 
result of competition with BH4 at the active site of the enzyme [23]. In addition, all the 
experimental interventions have been short term; there are no previous studies 
evaluating the effects as well as the tolerability of chronic low-dose BH4 augmentation 
on NOS function in vascular disease, which is crucial for translation of this concept into 
clinical practice. The present study validates previous investigations, and importantly, 
demonstrates that chronic supplementation with low dose BH4 is feasible and effective 
and may therefore represent a new approach for the treatment of early cardiovascular 
disease. 
  
In a clinical study it is not possible to determine whether BH4 is pharmacologically 
active through a specific effect on eNOS coupling in the endothelium, or whether BH4 
acts simply as a non-specific anti-oxidant.  To address this question, we performed 
parallel experiments using human aortic endothelial cells to add mechanistic insight to 
our clinical data. When human aortic endothelial cells were exposed to oxidized LDL 
we observed a reduction in cellular BH4 levels, together with a reduction in NO release 
and increased superoxide production. Inhibition of NOS by L-NAME reduced NO 
release in control endothelial cells, but not in LDL-exposed cells, indicating impaired 
NO synthesis after LDL exposure. In contrast, superoxide production from LDL-
 group.bmj.com on March 21, 2011 - Published by heart.bmj.comDownloaded from 
 11
exposed cells was reduced by L-NAME. This indicates that in LDL treated endothelial 
cells superoxide production is at least in part generated by uncoupled NOS. 
Importantly, supplementation of LDL-treated cells with exogenous BH4 , analogous to 
our clinical study, restored their phenotype to that of control cells, supporting the 
concept that reduced intracellular BH4 is responsible for NOS uncoupling. These 
observations are consistent with previous studies showing similar BH4-dependent 
responses of NO and superoxide production in explanted vessels from patients with 
diabetes [24].  
  
Oxidative stress is a common mechanism in pathogenesis of vascular disease, and 
accelerated oxidative degradation of BH4 may provide an explanation for the consistent 
beneficial effect observed in a variety of animal models and patients with endothelial 
dysfunction. This hypothesis is supported by observations that the antioxidant vitamin 
C is able to stimulate eNOS enzymatic activity by increasing intracellular concentration 
of BH4 [25][26]. Indeed, the effect of vitamin C appears to be mediated by chemical 
stabilization of BH4. 
 
Despite the striking results of our study, there are a number of potential limitations that 
remain to be addressed in translating BH4 treatment to wider clinical application. We 
measured plasma BH4 levels in patients, but this may not reflect endothelial BH4 
concentration or oxidative state. Indeed, the mechanisms involved in BH4 transport 
from plasma to endothelium, or the requirement for de novo BH4 synthesis in the 
endothelium remain unclear. Current formulations of BH4 are complex to deliver 
because the compound is readily oxidized at room temperature. Formulations with 
improved stability are needed before larger scale studies can be undertaken, and the 
optimal doses and timing of BH4 supplementation in vascular disease states are not yet 
defined. Finally, future large-scale clinical studies will be required to evaluate the 
effects of BH4 treatment on vascular disease progression and clinical events. However, 
recent data suggest that long-term therapy with BH4 in patients with 
hyperphenylalaninemia is feasible and safe [3][4]. Worldwide, several hundred patients 
are treated with the cofactor [27]. Some dose-dependent adverse reactions, including 
sleep disorders, polyuria and loose stools, were reported in a safety evaluation [27], 
none of which have been observed in this present study. 
 
In conclusion, we show for the first time that in hypercholesterolemia, endothelial 
dysfunction and oxidative stress can be normalized by chronic treatment with BH4. 
Thus, long-term supplementation with BH4 may provide a rational new approach to 
prevent and treat cardiovascular disease.  
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LEGENDS TO FIGURES 
 
 
 
Fig 1. Changes in BH4 and 8-F2 isoprostane plasma levels after 4-week 
treatment with BH4 or placebo. (A) BH4 levels were increased after oral 
BH4 supplementation whereas no change occurred in placebo group. (B) 
8-F2 isoprostanes were significantly decreased by BH4 compared with 
placebo. Data are mean ± SEM 
 
 
Fig 2. Effect of BH4 supplementation on endothelial function. Forearm blood flow 
(FBF) response to Acetycholine was significantly impaired in 
hypercholesterolemic subjects compared to controls and restored by a 4-
week oral BH4 supplementation. (AUC: area under the curve). Data are 
mean ± SEM 
 
 
 
Fig 3.  Intracellular BH4 levels and changes in NO and superoxide anion (O2-) 
production in control and human aortic endothelial cells incubated with 
native low density lipoproteins (LDL) at 100 mg cholesterol/dL for 6 hours. 
Bar graphs showing (A) BH4 levels, (B) NO release following stimulation 
with calcium ionophore A23187 (1 µmol/L), and (C) O2- production under 
basal conditions and after inhibition of eNOS by NG-nitro-L-arginine-
methyl ester (L-NAME, 3x10-4mol/L) or in the presence of exogenous BH4 
(10-4mol/L).  Data are mean ± SEM (n=3-8).  
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